

**REMARKS**

Reconsideration of this application is respectfully requested.

**STATUS OF THE CLAIMS**

Following entry of this Amendment, claims 12, 14, and 31-44 will be pending. Claims 1-11, 13, and 15-30 are cancelled. Claims 34-44 are added. Claims 31-33 are amended herein to correct the mis-numbering of those claims in applicants' prior amendment. The amendments are shown in the attached page.

The new claims relate to antibody antagonists, and to treatment of rheumatoid arthritis, psoriasis, and asthma. Support is found at page 18, lines 5-10, page 17, lines 6-9, and page 7, line 2.


**RESTRICTION REQUIREMENT**

The examiner has required restriction of the claims. Applicants elect the claims of group XIII, directed to treatment of inflammation. Non-elected claims are cancelled herein.

Respectfully submitted,

Dated: \_\_\_\_\_

Pfizer Inc  
150 East 42nd Street  
New York, NY 10017-5612  
(212) 733-3677

  
\_\_\_\_\_  
Seth H. Jacobs  
Attorney for the Applicants  
Reg. No. 32,140

**VERSION OF CLAIMS SHOWING CHANGES**  
**DO NOT ENTER**

3[2]1. A method of treating inflammation in a mammal comprising administering to said mammal an effective amount of an m-CSF inhibitor.

3[3]2. The method of claim 32 wherein said inhibitor is an antibody.

3[4]3. The method of claim 32 wherein said inflammation is associated with arthritis.--